These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 11005360)

  • 1. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
    Linder JD; Mönkemüller KE; Davis JV; Wilcox CM
    South Med J; 2000 Sep; 93(9):930-2. PubMed ID: 11005360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 6. [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances].
    Hinz B; Brune K
    Wien Klin Wochenschr; 1999 Feb; 111(3):103-12. PubMed ID: 10093892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-2-specific inhibition: implications for clinical practice.
    Pascucci RA
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COX-2 inhibitors: new drugs for the management of pain and inflammation.
    Hutchins V; Hutchins B
    Dent Today; 2001 Feb; 20(2):56-61. PubMed ID: 12524847
    [No Abstract]   [Full Text] [Related]  

  • 12. COX-1 and COX-2 inhibitors.
    Hawkey CJ
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):801-20. PubMed ID: 11566042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
    Tindall E
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COX-2 inhibitors.
    Brooks PM; Day RO
    Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Specific inhibitors of cyclooxygenase type 2] ].
    Tomasová-Studýnková J
    Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.
    Fung HB; Kirschenbaum HL
    Clin Ther; 1999 Jul; 21(7):1131-57. PubMed ID: 10463513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Drug Events Involving COX-2 Inhibitors.
    Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
    Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
    Peretz A
    Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
    Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.